A Study of Overall Survival in Participants With Unresectable Hepatocellular Carcinoma

Specific Use Results Survey of LENVIMA 4 mg Capsules -Observational Study of Overall Survival in Patients With Unresectable Hepatocellular Carcinoma (Study LEN03T)

The primary purpose of this study to continue follow-up of participants enrolled in the study E7080-M081-504 (NCT03663114) of lenvima capsules and to evaluate the overall survival of participants with hepatocellular carcinoma.

Inclusion Criteria:

- All participants enrolled in the study E7080-M081-504 with informed consent to participate in this study.

Exclusion Criteria:

• Participants who do not have unresectable hepatocellular carcinoma
• Participants who have not given informed consent or have withdrawn consent to participation
• Participants with a history of hypersensitivity to any ingredient of lenvima
• Pregnant or possibly pregnant women
• Participants previously treated with lenvima (excluding those previously enrolled in the Study E7080-M081-504 [NCT03663114] at another clinical site).